Evidence map›Paper›PMID 38745652›Full record

ArticleFrontiers in immunology2024

Myeloid cell expression of CD200R is modulated in active TB disease and regulates

Mohamed Ahmed, Liku B Tezera, Nicholas Herbert, Mark Chambers, Michaela T Reichmann, Kievershen Nargan, Henrik Kloverpris, Farina Karim, Mbali Hlatshwayo, Rajhmun Madensein and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mohamed AhmedAfrica Health Research Institute, Durban, South Africa.
Liku B TezeraNIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Nicholas HerbertAfrica Health Research Institute, Durban, South Africa.
Mark ChambersAfrica Health Research Institute, Durban, South Africa.
Michaela T ReichmannNIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Kievershen NarganAfrica Health Research Institute, Durban, South Africa.
Henrik KloverprisAfrica Health Research Institute, Durban, South Africa.
Farina KarimAfrica Health Research Institute, Durban, South Africa.
Mbali HlatshwayoAfrica Health Research Institute, Durban, South Africa.
Rajhmun MadenseinDepartment of Cardiothoracic Surgery, Nelson Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Munir HabeshDepartment of Cardiothoracic Surgery, Nelson Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Monjural HoqueKwadabeka Community Health Care Centre, Kwadabeka, South Africa.
Adrie J C SteynAfrica Health Research Institute, Durban, South Africa.
Paul T ElkingtonNIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Alasdair J LeslieAfrica Health Research Institute, Durban, South Africa.

Funding

Hydrogen Sulfide and Tuberculosis DiseaseR01AI134810 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI STEYN, ADRIE JC · 2018 to 2021
$2.2M
Medical Research Council MR/P023754/1Medical Research Council MR/W025728/1NIAID NIH HHS R01 AI134810Wellcome Trust 210662/Z/18/Z
6 · The paper itself

Abstract

A robust immune response is required for resistance to pulmonary tuberculosis (TB), the primary disease caused by

Indexed as

Mycobacterium tuberculosisMyeloid CellsTuberculosis, PulmonaryAdultAntigens, CDBiomimeticsFemaleHumansLungMacrophagesMaleMiddle AgedMonocytesOrexin ReceptorsAntigens, CDOrexin ReceptorsCD200 receptorimmune checkpointinnate immunitypulmonary infectiontuberculosis

Identifiers

PMID38745652
PMCPMC11091283

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.